Genentech, a member of the Roche Group, is expanding its initial investment in a new Holly Springs, NC manufacturing facility. The increased investment will more than double the commitment for the company’s first East Coast manufacturing facility to approximately $2 billion. The expansion builds on the company’s May 2025 investment announcement, as well as the project’s August 2025 groundbreaking.

Genentech will build out additional production capacity and significantly increase the facility’s output. Set to be operational by 2029, the facility will produce next-generation treatments for metabolic conditions, such as obesity. By leveraging advanced biomanufacturing, automation, and digital tools, the investment aims to boost efficiency and significantly expand Genentech’s U.S.-based supply chain.

The expanded investment is expected to add an additional 100 new jobs in North Carolina, with the project supporting more than 500 manufacturing jobs.

This expansion supports Roche and Genentech’s broader $50 billion commitment to U.S. manufacturing and shared goal with the U.S. administration to strengthen domestic production and innovation. Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states. 

Genentech CEO Ashley Magargee, said, “We are excited to further expand our investment in our state-of-the-art manufacturing facility in Holly Springs. This expansion reflects our long-term commitment to the U.S. and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible. This additional investment will create more high-quality jobs, strengthen local partnerships, and ensure a resilient supply of medicines for years to come.”